Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SS)
Nanchang, CN
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.65% | +10.21% | +4.72% | +0.76% | +15.33% | +8.11% | +8.63% | +0.52% | +119.74% | +80.09% | +2,022.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-4.9% Q1'26: -12.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+14.4% Q1'26: +2.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.3% Q1'26: +4.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+24.2% ★ Q1'26: +32.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+19.5% ★ Q1'26: +26.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.5% Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.30× ★ Q1'26: 0.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.60B
est: 3.18B (-18.3%)
|
1.55B
est: 1.59B (-2.8%)
|
1.75B
est: 1.78B (-2.0%)
|
1.76B
est: 1.89B (-7.3%)
|
2.45B
est: 2.34B (+4.8%)
|
2.44B
est: 2.70B (-9.6%)
|
2.87B
est: 3.24B (-11.2%)
|
3.89B
est: 3.77B (+3.0%)
|
4.55B
est: 4.20B (+8.4%)
|
4.44B
est: 4.41B (+0.6%)
|
4.22B
est: 4.32B (-2.2%)
|
4.51B
4.23B – 5.23B
+4.5% YoY
|
4.88B
4.52B – 5.78B
+8.1% YoY
|
5.31B
5.24B – 5.37B
+8.8% YoY
|
| EBITDA |
541.90M
est: 711.28M (-23.8%)
|
506.43M
est: 356.08M (+42.2%)
|
535.84M
est: 398.82M (+34.4%)
|
620.77M
est: 423.57M (+46.6%)
|
679.28M
est: 522.94M (+29.9%)
|
694.09M
est: 603.95M (+14.9%)
|
741.93M
est: 724.07M (+2.5%)
|
878.40M
est: 843.98M (+4.1%)
|
1.05B
est: 1.32B (-20.4%)
|
1.16B
est: 1.38B (-16.0%)
|
1.17B
est: 1.35B (-13.3%)
|
1.41B
1.33B – 1.64B
+4.5% YoY
|
1.53B
1.42B – 1.81B
+8.1% YoY
|
1.66B
1.64B – 1.68B
+8.8% YoY
|
| EBIT |
474.07M
est: 600.41M (-21.0%)
|
440.69M
est: 300.58M (+46.6%)
|
472.98M
est: 336.65M (+40.5%)
|
548.23M
est: 357.54M (+53.3%)
|
566.30M
est: 441.42M (+28.3%)
|
581.32M
est: 509.80M (+14.0%)
|
627.02M
est: 611.20M (+2.6%)
|
758.32M
est: 712.42M (+6.4%)
|
923.95M
est: 1.18B (-21.9%)
|
1.03B
est: 1.24B (-17.2%)
|
1.02B
est: 1.21B (-16.0%)
|
1.27B
1.19B – 1.47B
+4.5% YoY
|
1.37B
1.27B – 1.63B
+8.1% YoY
|
1.49B
1.48B – 1.51B
+8.8% YoY
|
| Net Income |
367.01M
est: 334.64M (+9.7%)
|
379.76M
est: 395.73M (-4.0%)
|
417.80M
est: 458.13M (-8.8%)
|
470.25M
est: 455.46M (+3.2%)
|
463.60M
est: 525.74M (-11.8%)
|
473.74M
est: 586.42M (-19.2%)
|
505.69M
est: 718.83M (-29.7%)
|
598.24M
est: 719.88M (-16.9%)
|
718.67M
est: 747.25M (-3.8%)
|
788.19M
est: 816.84M (-3.5%)
|
906.12M
est: 909.82M (-0.4%)
|
988.55M
969.66M – 1.01B
+8.7% YoY
|
1.08B
1.06B – 1.14B
+9.5% YoY
|
1.21B
1.16B – 1.25B
+11.4% YoY
|
| SGA |
787.91M
est: 1.30B (-39.5%)
|
632.83M
est: 652.36M (-3.0%)
|
681.18M
est: 730.65M (-6.8%)
|
598.33M
est: 776.00M (-22.9%)
|
1.04B
est: 958.05M (+8.1%)
|
962.24M
est: 1.11B (-13.0%)
|
1.20B
est: 1.33B (-9.8%)
|
1.71B
est: 1.55B (+10.8%)
|
1.86B
est: 1.69B (+9.9%)
|
1.72B
est: 1.78B (-3.0%)
|
1.53B
est: 1.74B (-12.3%)
|
1.82B
1.71B – 2.11B
+4.5% YoY
|
1.97B
1.82B – 2.33B
+8.1% YoY
|
2.14B
2.11B – 2.17B
+8.8% YoY
|
| EPS |
0.58
est: 0.53 (+9.3%)
|
0.60
est: 0.63 (-4.4%)
|
0.66
est: 0.73 (-9.2%)
|
0.75
est: 0.72 (+3.8%)
|
0.74
est: 0.83 (-11.2%)
|
0.75
est: 0.93 (-19.4%)
|
0.80
est: 1.14 (-29.8%)
|
0.95
est: 1.14 (-16.8%)
|
1.00
est: 1.18 (-15.2%)
|
1.25
est: 1.24 (+1.0%)
|
1.43
est: 1.41 (+1.6%)
|
1.56
1.53 – 1.59
+10.8% YoY
|
1.72
1.67 – 1.80
+10.4% YoY
|
1.90
1.83 – 1.97
+10.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets High Dividend Fund DEM | 0.01% | 495.4K | 0.63% |
| 2 | WisdomTree Emerging Markets Equity Income UCITS ETF DEMD.L | 0.01% | 31.2K | 0.46% |
| 3 | WisdomTree Emerging Markets Equity Income UCITS ETF - Acc DEMR.L | 0.01% | 31.2K | 0.46% |
| 4 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.01% | 23.2K | 0.44% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 571.0K | 0.06% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 20.9K | 0.44% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 270.8K | 0.39% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 151.3K | 0.29% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 42.8K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.0K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Weili Zhou | Accounting Supervisor | — | female |
| Wenbin Xiao | General Manager | — | male |
| Xiaojun Li | Financial Controller & Financial Director | — | male |
| Yongjing Tian | Secretary of the Board of Directors | — | female |
| Yongqian Xu | CEO & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600750.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
